Literatur
- 1 Deutsche Krebsgesellschaft .Kurzgefasste Interdisziplinäre Leitlinien 2002. 2002
3
- 2
Ensink F BM, Beck D, Bautz M T, Hanekop G G.
Tumorschmerztherapie Teil 1: Prävalenz und Klassifikation von Tumorschmerzen.
Niedersächsisches Ärzteblatt.
1999;
72
1-4
- 3
Cleeland C S, Gonin R, Hatfield A K, Edmonson J H, Blum R H, Stewart J A, Pandya K J.
Pain and its treatment in outpatients with metastatic cancer.
N Engl J Med.
1994;
330
(9)
592-596
- 4 Bonica J J.
Cancer pain,. in: Bonica J.J The management of pain. Lea & Fiebiger: Philadelphia/London 1990:
400-460
- 5
Caraceni A, Portenoy R K.
An international survey of cancer pain characteristics and syndromes. IASP Task Force
on Cancer Pain. International Association for the Study of Pain.
Pain.
1999;
82
(3)
263-74
- 6 Heidemann E.
Malignome und Prävalenz von Schmerz,. in: H. Beck, et al Schmerztherapie. Thieme: Stuttgart/New York 2002: 515-517
- 7
Portenoy R K.
Cancer pain. Epidemiology and syndromes.
Cancer.
1989;
63
(11 Suppl)
2298-2307
- 8
Twycross R.
Cancer pain classification.
Acta Anaesthesiol Scand.
1997;
41
(1 Pt 2)
141-145
- 9
Deutsche Gesellschaft für Anästhesie und Intensivmedizin .
Grenzen der intensivmedizinischen Behandlungspflicht.
Anästhesie & Intensivmedizin.
1999;
40
(2)
99ff
- 10
Gonzales G R, Elliott K J, Portenoy R K, Foley K M.
The impact of a comprehensive evaluation in the management of cancer pain.
Pain.
1991;
47
(2)
141-144
- 11
Schug S A, Zech D, Dorr U.
Cancer pain management according to WHO analgesic guidelines.
J Pain Symptom Manage.
1990;
5
(1)
27-32
- 12 World-Health-Organisation .Cancer pain relief. Genf: World Health Organisation
1986
- 13
Zech D F, Grond S, Lynch J, Hertel D, Lehmann K A.
Validation of World Health Organization Guidelines for cancer pain relief: a 10-year
prospective study.
Pain.
1995;
63
(1)
65-76
- 14
Ventafridda V, Tamburini M, Caraceni A, de Conno F, Naldi F.
A validation study of the WHO method for cancer pain relief.
Cancer.
1987;
59
(4)
850-856
- 15
Jadad A R, Browman G P.
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its
evaluation.
Jama.
1995;
274
(23)
1870-1873
- 16
Mukherjee D, Nissen S E, Topol E J.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Jama.
2001;
286
(8)
954-959
- 17
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M B,
Hawkey C J, Hochberg M C, Kvien T K, Schnitzer T J.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients
with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med.
2000;
343
(21)
1520-1528, 2 p following 1528
- 18
Silverstein F E, Faich G, Goldstein J L, Simon L S, Pincus T, Whelton A, Makuch R,
Eisen G, Agrawal N M, Stenson W F, Burr A M, Zhao W W, Kent J D, Lefkowith J B, Verburg K M,
Geis G S.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs
for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled
trial. Celecoxib Long-term Arthritis Safety Study.
Jama.
2000;
284
(10)
1247-1255
- 19
Henry D, Lim L L-Y, Rodriguez L AG, Gutthann S P, Carson J L, Griffin M, Savage R,
Logan R, Moride Y, Hawkey C, Hill S, Fries J T.
Variability in risk of gastrointestinal complications with individual non-steroidal
anti-inflammatory drugs: results of a collaborative meta-analysis.
BMJ.
1996;
312
(7046)
1563-1566
- 20
Juni P, Rutjes A W, Dieppe P A.
Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory
drugs?.
BMJ.
2002;
324
(7349)
1287-1288
- 21
Blanke C D.
Celecoxib with chemotherapy in colorectal cancer.
Oncology (Huntingt).
2002;
16
(4 Suppl 3)
17-21
- 22
Edwards J G, Faux S P, Plummer S M, Abrams K R, Walker R A, Waller D A, O'Byrne K J.
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
Clin Cancer Res.
2002;
8
(6)
1857-1862
- 23
Ventafridda V, de Conno F, Panerai A E, Maresca V, Monza G C, Ripamonti C.
Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind,
within-patient study comparing nine drugs.
J Int Med Res.
1990;
18
(1)
21-29
- 24
Bjorkman R, Hallman K M, Hedner J, Hedner T, Henning M.
Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P.
Pain.
1994;
57
(3)
259-264
- 25
Kornhuber J, Maler M, Wiltfang J, Bleich S, Degner D, Ruther E.
[Neuronal potassium channel opening with flupirtine].
Fortschr Neurol Psychiatr.
1999;
67
(10)
466-475
- 26
Schwarz M, Schmitt T, Pergande G, Block F.
N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant
action of flupirtine on spinal reflexes in rats.
Eur J Pharmacol.
1995;
276
(3)
247-255
- 27
Friedel H A, Fitton A.
Flupirtine. A review of its pharmacological properties, and therapeutic efficacy
in pain states.
Drugs.
1993;
45
(4)
548-569
- 28
arznei-telegramm .
Leberschäden durch Analgetikum. Flupirtin.
2000;
31
(3)
30
- 29
Eichelbaum M, Evert B.
Influence of pharmacogenetics on drug disposition and response.
Clin Exp Pharmacol Physiol.
1996;
23
(10-11)
983-985
- 30
Lewis K S, Han N H.
Tramadol: a new centrally acting analgesic.
Am J Health Syst Pharm.
1997;
54
(6)
643-652
- 31
Wehrmann T, Rausch D, Seiler K U, Brennscheidt U, Caspary W F.
Tilidine does not affect human sphincter of Oddi motility - a randomized, controlled
study.
Aliment Pharmacol Ther.
1997;
11
(5)
987-992
- 32
Hanks G W, Conno F, Cherny N, Hanna M, Kalso E, McQuay H J, Mercadante S, Meynadier J,
Poulain P, Ripamonti C, Radbruch L, Casas J R, Sawe J, Twycross R G, Ventafridda V.
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
Br J Cancer.
2001;
84
(5)
587-593
- 33
Heiskanen T, Kalso E.
Controlled-release oxycodone and morphine in cancer related pain.
Pain.
1997;
73
(1)
37-45
- 34
Hagen N A, Babul N.
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation
and controlled-release hydromorphone in the treatment of cancer pain.
Cancer.
1997;
79
(7)
1428-1437
- 35
Grond S, Radbruch L, Lehmann K A.
Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.
Clin Pharmacokinet.
2000;
38
(1)
59-89
- 36
Donner B, Zenz M, Strumpf M, Raber M.
Long-term treatment of cancer pain with transdermal fentanyl.
J Pain Symptom Manage.
1998;
15
(3)
168-175
- 37
Jeal W, Benfield P.
Transdermal fentanyl. A review of its pharmacological properties and therapeutic
efficacy in pain control.
Drugs.
1997;
53
(1)
109-138
- 38
Ahmedzai S, Brooks D.
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference,
efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.
J Pain Symptom Manage.
1997;
13
(5)
254-261
- 39
Donner B, Zenz M, Tryba M, Strumpf M.
Direct conversion from oral morphine to transdermal fentanyl: a multicenter study
in patients with cancer pain.
Pain.
1996;
64
(3)
527-534
- 40 Arzneimittelkommision-der-deutschen-Ärzteschaft .Therapieempfehlungen Tumorschmerz. 2000
2
- 41
Portenoy R K, Payne R, Coluzzi P, Raschko J W, Lyss A, Busch M A, Frigerio V, Ingham J,
Loseth D B, Nordbrock E, Rhiner M.
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in
cancer patients: a controlled dose titration study.
Pain.
1999;
79
(2-3)
303-312
- 42
Coluzzi P H, Schwartzberg L, Conroy J D, Charapata S, Gay M, Busch M A, Chavez J,
Ashley J, Lebo D, McCracken M, Portenoy R K.
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl
citrate (OTFC) and morphine sulfate immediate release (MSIR).
Pain.
2001;
91
1-2.
123-130
- 43
Plummer J L, Gourlay G K, Cherry D A, Cousins M J.
Estimation of methadone clearance: application in the management of cancer pain.
Pain.
1988;
33
(3)
313-322
- 44
Gorman A L, Elliott K J, Inturrisi C E.
The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate
(NMDA) receptor in rat forebrain and spinal cord.
Neurosci Lett.
1997;
223
(1)
5-8
- 45
Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C.
Switching from morphine to methadone to improve analgesia and tolerability in cancer
patients: a prospective study.
J Clin Oncol.
2001;
19
(11)
2898-2904
- 46
Bulka A, Plesan A, Xu X J, Wiesenfeld-Hallin Z.
Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine
in a rat model of mononeuropathy.
Pain.
2002;
95
(1-2)
103-109
- 47
Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, de Conno F.
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic
dose ratio?.
J Clin Oncol.
1998;
16
(10)
3216-3221
- 48
Rowbotham M C, Reisner-Keller L A, Fields H L.
Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia.
Neurology.
1991;
41
(7)
1024-1028
- 49
Dellemijn P L, Vanneste J A.
Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl
in neuropathic pain.
Lancet.
1997;
349
(9054)
753-758
- 50
McQuay H J, Tramer M, Nye B A, Carroll D, Wiffen P J, Moore R A.
A systematic review of antidepressants in neuropathic pain.
Pain.
1996;
68
(2-3)
217-227
- 51
Kingery W S.
A critical review of controlled clinical trials for peripheral neuropathic pain and
complex regional pain syndromes.
Pain.
1997;
73
(2)
123-139
- 52
Kalso E, Tasmuth T, Neuvonen P J.
Amitriptyline effectively relieves neuropathic pain following treatment of breast
cancer.
Pain.
1996;
64
(2)
293-302
- 53
Baron R.
[Neuropathic pain. The long path from mechanisms to mechanism-based treatment].
Anaesthesist.
2000;
49
(5)
373-386
- 54
Ventafridda V, Bianchi M, Ripamonti C, Sacerdote P, de Conno F, Zecca E, Panerai A E.
Studies on the effects of antidepressant drugs on the antinociceptive action of morphine
and on plasma morphine in rat and man.
Pain.
1990;
43
(2)
155-162
- 55
Max M B, Lynch S A, Muir J, Shoaf S E, Smoller B, Dubner R.
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
N Engl J Med.
1992;
326
(19)
1250-1256
- 56
Feuerstein T J.
Antidepressiva zur Therapie chronischer Schmerzen. Metaanalyse.
Der Schmerz.
1997;
11
213-226
- 57
McQuay H J, Moore R A.
Antidepressants and chronic pain.
Bmj.
1997;
314
(7083)
763-764
- 58
McQuay H, Carroll D, Jadad A R, Wiffen P, Moore A.
Anticonvulsant drugs for management of pain: a systematic review.
Bmj.
1995;
311
(7012)
1047-1052
- 59 McNamara J O.
Drugs effective in the Therapy of Epilepsies, in Goodman & Gillman's. J.G. Hardman and L.E. Limbird, Editors The pharmacological Basis of Therapeutics. Mc
Graw-Hill: New York 2001: 521-547
- 60
Dirks J, Fredensborg B B, Christensen D, Fomsgaard J S, Flyger H, Dahl J B.
A randomized study of the effects of single-dose gabapentin versus placebo on postoperative
pain and morphine consumption after mastectomy.
Anesthesiology.
2002;
97
(3)
560-564
- 61
Caraceni A, Zecca E, Martini C, de Conno F.
Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.
J Pain Symptom Manage.
1999;
17
(6)
441-445
- 62
Clezardin P, Gligorov J, Delmas P.
Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the
treatment of malignant osteolysis.
Joint Bone Spine.
2000;
67
(1)
22-29
- 63
Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C.
The role of bisphosphonates in the treatment of painful metastatic bone disease: a
review of phase III trials.
Pain.
1998;
78
(3)
157-169
- 64
Pavlakis N, Stockler M.
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev.
2002;
1
CD003474
- 65
Zimmer A, Zimmer A M, Hohmann A G, Herkenham M, Bonner T I.
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout
mice.
Proc Natl Acad Sci USA.
1999;
96
(10)
5780-5785
- 66
Zygmunt P M, Andersson D A, Hogestatt E D.
Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves
via a CB1 and CB2 cannabinoid receptor-independent mechanism.
J Neurosci.
2002;
22
(11)
4720-4727
- 67
Campbell F A, Tramer M R, Carroll D, Reynolds D J, Moore R A, McQuay H J.
Are cannabinoids an effective and safe treatment option in the management of pain?
A qualitative systematic review.
Bmj.
2001;
323
(7303)
13-16
- 68
Pappagallo M.
Incidence, prevalence, and management of opioid bowel dysfunction.
Am J Surg.
2001;
182
(5A Suppl)
11S-18S
- 69
Yeomans N D, Tulassay Z, Juhasz L, Racz I, Howard J M, van Rensburg C J, Swannell A J,
Hawkey C J.
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal
antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated
Ulcer Treatment (ASTRONAUT) Study Group.
N Engl J Med.
1998;
338
(11)
719-726
- 70
Eisenberg E, Berkey C S, Carr D B, Mosteller F, Chalmers T C.
Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis.
J Clin Oncol.
1994;
12
(12)
2756-2765
- 71
Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F.
Rapid titration with intravenous morphine for severe cancer pain and immediate oral
conversion.
Cancer.
2002;
95
(1)
203-208
- 72
Eisenberg E, Carr D B, Chalmers T C.
Neurolytic celiac plexus block for treatment of cancer pain: a meta- analysis.
Anesth Analg.
1995;
80
(2)
290-295
- 73
Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S.
Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients
with pancreatic cancer.
Br J Surg.
1998;
85
(2)
199-201
- 74
Kawamata M, Ishitani K, Ishikawa K, Sasaki H, Ota K, Omote K, Namiki A.
Comparison between celiac plexus block and morphine treatment on quality of life in
patients with pancreatic cancer pain.
Pain.
1996;
64
(3)
597-602
- 75 Gutstein H B, Akil H.
Opioid Analgesics. J.G. Hardman and L.E. Limbird, Editors Goodman & Gillman's The pharmacological Basis
of Therapeutics. Mc Graw-Hill: New York 2001: 569-620
Dr. Henning Ohnesorge
Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Kiel
Schwanenweg 21
24105 Kiel
Email: ohnesorge@anaesthesie.uni-kiel.de
